New Awards for DNA Sequencing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BETHESDA, Md--The National Center for Human Genome Research at the NIH has announced six research grants that are expected to propel forward the final phase of the Human Genome Project, headed by Dr. Francis Collins.

BETHESDA, Md--The National Center for Human Genome Research atthe NIH has announced six research grants that are expected topropel forward the final phase of the Human Genome Project, headedby Dr. Francis Collins.

The grants, ranging from $1 million to $6.7 million a year forup to 3 years, are meant to accelerate the process of automatedDNA sequencing. The recipient institutions are The Institute forGenomic Research; Baylor College of Medicine; the Whitehead Institute-MITGenome Center; Stanford University; University of Washington,Seattle; and Washington University.

A requirement of the awards is that the researchers release theirnew sequencing data quickly to the scientific community, includingreports on a World Wide Web page.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content